02216nas a2200421   4500000000100000008004100001260001600042653001700058653002400075653002100099653002300120100001700143700001300160700001400173700001400187700001400201700001500215700001100230700001500241700001500256700001100271700001500282700001400297700001600311700001700327700001600344700001200360700001200372700001600384700001500400700001200415700001600427245010900443300001100552490000800563520120900571022001401780       2021                            d  bElsevier BV10aParasitology10aInfectious Diseases10aGeneral Medicine10apraziquantel (PZQ)1 aEnabulele EE1 aPlatt RN1 aAdeyemi E1 aAgbosua E1 aAisien MS1 aAjakaye OG1 aAli MU1 aAmaechi EC1 aAtalabi TE1 aAuta T1 aAwosolu OB1 aDagona AG1 aEdo-Taiwo O1 aEjikeugwu CE1 aIgbeneghu C1 aNjom VS1 aOrji MN1 aOyinloye FO1 aOzemoka HJ1 aUgah UI1 aAnderson TJ00aUrogenital schistosomiasis in Nigeria post receipt of the largest single praziquantel donation in Africa  a1059160 v2193 aSchistosomiasis control efforts in Nigeria received a boost in 2016 when Merck Group made the largest single donation of praziquantel to an African country. We examined urine samples from 2,023 school age children from 15 locations in 10 states and an Internally Displaced Person's (IDP) camp in Nigeria. We recorded an overall Schistosoma haematobium prevalence of 10.4% in the 10 states that ranged between 6 – 37%, while prevalence in the IDP camp was 2.9%. The highest infection prevalence (37%) recorded was from the population in Wasai Dam area in Minjibir (Kano State), while five locations had no positive urine samples. We observed heavy intensity of infection (≥ 50 eggs/10 ml urine) in 87.9% of infected samples and co-occurrence of the eggs of S. haematobium and S. mansoni in urine for two participants. The overall prevalence we recorded is slightly above the national average (9.5%) reported in 2015. Our findings indicate that despite the ongoing administration of praziquantel in Nigeria, urogenital schistosomiasis is still prevalent with heavy intensity of infection. Large-scale epidemiological monitoring is required to monitor the efficacy of schistosomiasis control in Nigeria.  a0001-706X